v3.20.4
Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Jun. 30, 2018
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Cash outflows related to other acquisitions and investments       $ 1,350 $ 1,135 $ 736
Acquired in-process research and development       1,198 385 424
Goodwill       33,124 15,604 15,663
Other operating expense (income)       0 890 (500)
Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Additional contribution to collaboration     $ 500      
I-Mab Biopharma | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Potential additional milestone payments       1,700    
Genmab A/S | Maximum | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Potential additional milestone payments       3,200    
Reata Pharmaceuticals Inc            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Consideration received for acquired rights       250    
Consideration receivable for acquired rights       80    
Other operating expense (income)         330  
Calico Life Sciences LLC | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Additional contribution to collaboration by partner     $ 500      
Term by which the agreement was extended     3 years      
Other operating expense (income)         (500)  
Other individually insignificant arrangements | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Acquired in-process research and development       248 $ 385 $ 424
Other individually insignificant arrangements | Maximum | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Potential additional milestone payments       5,100    
Luminera            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Accounting purchase price $ 186          
Upfront payment to Luminera shareholders 122          
Contingent consideration 64          
Maximum future payments upon achievement of certain milestones 90          
Intangible assets - Developed product rights 127          
Intangible assets - In-process research and development 33          
Goodwill $ 12          
Other operating income | Reata Pharmaceuticals Inc            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Total consideration for acquired rights   $ 330        
In-process research and development | I-Mab Biopharma | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Acquired in-process research and development       200    
Upfront payment       180    
Milestone payment       20    
In-process research and development | Genmab A/S | Collaborative arrangement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Acquired in-process research and development       $ 750